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Objective: To evaluate the therapeutic effect of transplanted glial cell derived neurotrophic
factor (GDNF) modified marrow stromal cells (MSCs) on an experimental ischemic brain
injury based on the behavioral, morphological, and immunohistochemical observations.
Methods: The MSCs from four-week newborn rats were cultured in vitro. The cerebral
ischemia and reperfusion model was established in adult Sprague–Dawley (SD) rats
by using the suture method. Three days after model establishment, the animals were
injected with prepared MSCs via their caudal veins. The animals were then divided into
a sham-operation group, ischemia group, MSCs transplantation group, or GDNF+MSCs
transplantation group and were scored for their neurobehavioral manifestations at 3, 14,
and 28 days after the transplantation was performed. At this time, the survival condition
of intracerebral transplanted cells was measured by laser confocal microscopy while
the effect of transplantation on the GDNF expression in the ischemic brain tissue was
evaluated. Results: The MSCs cells transfected with GDNF gene were characterized by
green fluorescence. Three days after the transplantation, the animals that underwent
the cell transplantation showed significantly better behavioral data than the controls.
Fourteen days after transplantation, the animals transplanted with GDNF gene modified
MSCs were better than those transplanted with common MSCs. As compared with
common MSCs transplantation, GDNF+MSCs transplantation was significantly more
effective in reducing apoptotic cell volume and enhancing Bcl-2 expression, which was
favorable for the ischemic brain injury. Conclusions: Transplanted GDNF modified MSCs
can improve the nervous function and have a protective effect on the ischemic brain injury
through reducing apoptotic cell volume and enhancing the expression of anti-apoptotic
gene Bcl-2.
Keywords: marrow stromal cells (MSCs), glial cell derived neurotrophic factor (GDNF), cerebral ischemia, Bcl-2,
apoptosis
INTRODUCTION
As a principle component of non-hematopoietic system in bone
marrow, marrow stromal cells (MSCs) (Shichinohe et al., 2008;
Zacharek et al., 2010; Yilmaz et al., 2011) can express multiple
neuron- and gliocyte-specific markers and grow morphological
processes similar to that of neural cells when treated with inducers
in vitro. This indicates the potential of MSCs to differentiate into
neural cells and thus provides theoretical evidence for cell trans-
plantation in treating ischemic brain injuries. Glial cell derived
neurotrophic factor (GDNF) (Oppenheim et al., 1995) is a potent
neurotrophic factor, playing an important role in the differentia-
tion, development, growth, and survival of the cells in the central
nervous system.
In the present study, MSCs were cultured using the adherence
method. The expression vector was constructed after the GDNF
gene was cloned from rats. TheMSCs cultured in vitro were trans-
fected with cationic liposome-mediated eukaryotic expression
pDNA3-GDNF. The expressed green fluorescent protein was con-
sidered the reporter gene to optimize the transfection condition.
The transgenic MSCs obtained through screening were consid-
ered as the cell transplantation tracer. The focal brain ischemia
model was established in rats by using the suture method and
was transplanted with GDNF modified MSCs. The apoptotic cell
volume and expression of Bcl-2 before and after the transplan-
tation were observed in order to evaluate the mechanisms of the
protective effect of the exogenous stem cell and the neurotrophic
factor on brain ischemia. This will provide theoretical evidence
for the clinical application of cell and gene therapy for ischemic
cerebrovascular diseases.
MATERIALS AND METHODS
ANIMALS AND REAGENTS
Adult Sprague–Dawley (SD) rats, male and female, weigh-
ing between 250 g and 300 g, and four-week-old newborn rats
were purchased from Laboratory Animal Center of Chongqing
Medical University. Rabbit anti-Bcl-2 antibody was purchased
from Jingmei (Shanghai, China). Cationic liposome-mediated
eukaryotic expression pDNA3-GDNF plasmid (constructed in
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our laboratory) carrying green fluorescent protein was used to
transfect MSCs cultured in vitro.
ANIMAL MODEL
Rightmiddle cerebral artery occlusion (MCAO) was induced with
an intraluminal filament as previously reported (Longa et al.,
1989). Transient right MCAO was induced for two hours by
advancing a 40mm length monofilament nylon suture with its
tip rounded by heating near a flame to block the origin of the
MCA. Reperfusion was performed by withdrawal of the suture
two hours after MCAO. Animals subjected to sham surgery were
treated similarly, except that the filament was not advanced to
the origin of the MCA. Rats that failed to exhibit neurologi-
cal abnormalities at two hours after stroke were excluded from
this study.
CULTURING AND IDENTIFICATION OF MSCs FROM NEWBORN
RATS AND GDNF GENE TRANSFECTION
The MSCs from newborn rats were successfully cultured using
the adherence method after serial passage. Four-week-old SD rats
received the left hindquarter amputation. The rat bone marrow
was harvested from femur and tibia that were just amputated.
Flushed out the bone marrow, separated the mononuclear cell
layer, add the culture liquid α-Minimal Essential Medium (MEM)
which contains 10% serum of fetal cow to the cell-floating liq-
uid and plant them in the culture instruments in the condition of
37◦C and 5% CO2 for the primary generation culture. The third
and fourth generation cells grow well, and the amount cells more
than primary generation.
The GDNF gene expression vector was constructed after the
gene was cloned from rats. TheMSCs cultured in vitrowere trans-
fected with pDNA3-GDNF which was expressed by eukaryocytes
under the mediation of cationic liposome. The expressed green
fluorescent protein was considered the reporter gene in order
to optimize the transfection condition. The transgenic MSCs
obtained through screening were considered the cell transplan-
tation tracers.
ANIMAL GROUPING
The animals with related nervous symptoms were divided ran-
domly into three groups: untreated ischemia group (Group A),
MSCs transplantation group (Group B), and MSCs+GDNF
group (Group C). Each group included 30 animals used for the
evaluation at three separate time points (3, 14, and 28 days after
transplantation).
PREPARATION OF DONOR CELL SUSPENSION
AND TRANSPLANTATION PROCEDURE
The well-grown MSCs previously transplanted with pcDNA3-
GDNF-GFP plasmid were digested into monoplast suspension
with 0.25% trypsin and centrifuged at 800 rpm for five minutes.
The precipitated cells were re-suspended in 500μl normal saline
and gently beat with a pipette before they were transferred into
an Eppendorf (EP) tube where they were centrifuged at 800 rpm
for another five minutes. The precipitated cells were then re-
suspended in 100μl normal saline and incubated at 37◦C in a
5% CO2 incubator to be stored for use. Before use, the cells
were centrifuged again and the final concentration of the cells
obtained was 5 × 106/ml. The transplantation was conducted
intravenously via the bilateral caudal veins at 72 hours after
ischemia model was successfully established. Each animal in
GDNF+MSCs transplantation group (Group C) was injected
with 500μl of cell suspension. The syringe needle was slowly
withdrawn before after being retained in the vein for two min-
utes. The animals in MSCs transplantation group (Group B) were
injected with 500μl of common MSCs suspension. The animals
in untreated ischemia group (Group A) were injected with same
volume of sterilized normal saline via the same route.
FUNCTIONAL TESTS
A behavioral rating scale to grade the extent of injury was modi-
fied from published scales (Bederson et al., 1986). Three behav-
iors were tested: ipsilateral circling, bilateral grasp, and beam
walking. The extent of circling to the side of the infusion was
graded from 0 (no circling) to 4 (always circled). Grasp was tested
by placing the rat’s paws on the edge of a box 14 inches high;
strength of the hemiparetic paw was graded from 0 (grasped well)
to 4 (unable to grasp with forepaw). Beam walking was graded by
placing each rat on a beam; a grade of 0 indicated that it easily
traversed the beam, while a grade of 4 was given those unable to
walk on the beam. A total injury score was calculated as the sum
of the grades on the three tests. The higher score, the more severe
the injury.
SPECIMEN COLLECTION AND IMMUNOHISTOCHEMICAL
EXAMINATION
At 3, 14, and 28 days after transplantation, the animals were ter-
minated. Their brain tissue was fixed using normal saline and
4% paraformaldehyde through cardiac perfusion. Each half por-
tion of the specimen was used to prepare frozen and paraffin
embedded coronal sections (3μm). Every five successive sec-
tions were selected from every 200 sections. The sections selected
were deparaffinaged, treated in microwave for antigen repair,
added with rabbit anti-Bcl-2 antibody (1:100, Santa Cruz) and
incubated at 4◦C overnight. After the secondary antibody was
added, they were treated with chromogenic agent DAB, dehy-
drated, cleared, and sealed. The replacement of primary antibody
by PBS was used in the negative control. Under microscope, the
positive cell was characterized by brown, stained cytoplasm.
TUNEL ASSAY
After the sections were deparaffinaged as per usual, protease
K was added and the sections were incubated in a 25◦C wet
box for 30 minutes. Then, each of the sections was added with
50μl of TUNEL mixed solution (The TUNEL kit was purchased
from Tongfang [Beijing, China]) and incubated in a 25◦C wet
box for 60 minutes. After that, they were added with POD,
50μl/section, for transformation, and incubated in a 25◦C wet
box for 30minutes. The sections were then treated with chro-
mogenic DAB, dehydrated, cleared, and sealed. In the negative
control, the TUNEL mixed solution was replaced by a labeling
solution that did not contain large Klenow fragments. The posi-
tive cell was characterized by a brown stained nucleus with clear
background. Under microscope, the positive cells in the graticule
field were counted by using the micrometer of the 16D eyepiece
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while the values obtained were averaged as the positive cell density
of each animal.
STATISTICAL MANAGEMENT
The database and corresponding statistical analyses were per-
formed using statistical software SPSS 10.0. T-test, ANOVA,
and LSD analysis were used in the comparison between groups.
p < 0.05 was considered to be statistically significant.
RESULTS
IN VITRO CULTURING, IDENTIFICATION AND GDNF
GENE MODIFICATION OF RAT MSCs
The MSCs became adherent and grew into colonies with
extended and enlarged processes at 4–5 days after primary culture
(Figure 1). The modifiedMSCs were obtained when the common
MSCs were transfected with well-constructed pcDNA3-GDNF
plasmid mediated by cationic liposome. Microscopically, the
nuclei and cytoplasm of the differentiated cells showed green flu-
orescence indicating a successful transfection. Fourteen days after
transplantation, the number of fluorescent cells inMCSs-pcDNA-
GDNF-GFP group was greater than that of the cells in MSCs-
pcDNA-GFP group. The fluorescent cells in the former group
also had better configuration and stronger fluorescence inten-
sity. Twenty-eight days after transplantation, the morphologically
regular fluorescent cells in the MCSs-pcDNA-GDNF-GFP group
were distributed extensively in the brain tissue (Figure 2).
NEUROBEHAVIORAL SCORING FINDINGS
The animals in all groups showed obvious cerebral ischemic
symptoms after the experimental model was established. At
three days after transplantation, both the animals in the MSCs
FIGURE 1 | The successfully cultured MSCs.
transplantation group and MSCs+GDNF transplantation group
had significantly better neurobehavioral scores than those in
the ischemia group, suggesting the effect of transplanted MSCs
on the nervous function of the rats with cerebral infarction.
Meanwhile, three days after the transplantation, the animals in the
MSCs+GDNF transplantation group had a mildly better neu-
robehavioral scores than those in MSCs transplantation group
(7.27 ± 1.25 vs. 6.84 ± 1.12). And, 14 and 28 days after transplan-
tation, the behavioral score of the MSCs+GDNF transplantation
group was significantly better than that of the MSCs transplanta-
tion group, suggesting the superiority of GDNF modified MSCs
transplantation (See Table 1).
TUNEL FINDINGS
Three days after transplantation, the MSCs group and
MSCs+GDNF group had fewer apoptotic cells than the
ischemia group (P < 0.05), but similar apoptotic cell volume.
The value of apoptotic cells in Groups A, B, and C were 76 ± 7.44,
68 ± 8.19, and 65 ± 8.81, respectively. After transplantation, the
value decreased to 51 ± 8.27, 42 ± 6.28, and 35 ± 4.06 at day 14
and 33 ± 9.31, 24 ± 7.35, and 18 ± 6.85 at day 28. From the data,
it could be seen that the TUNEL positive cells decreased more
significantly in the MSCs group and the MSCs+GDNF group
(P < 0.05). Moreover, the apoptotic cells located at the cortex
around the ischemic region in the MSCs+GDNF group were
significantly fewer than those in the MSCs group, suggesting that
the transplanted GDNF modified MSCs could conspicuously
suppress the apoptosis of neurons (Figures 3, 4, and 5).
FIGURE 2 | Findings at 28 days after GDNF+MSCs transplantation.
Table 1 | The neurobehavioral scores in each group rats at different time points (x¯ ± s).
Group Before Three days after 14 days after 28 days after
transplantation transplantation transplantation transplantation
Untreated ischemia group (Group A) 9.02 ± 1.62 9.06 ± 1.44a 5.78 ± 1.33a 4.65 ± 0.82a
MSCs transplantation group (Group B) 8.67 ± 0.98 7.27 ± 1.25b 4.59 ± 0.76b 3.32 ± 0.41b
MSCs+GDNF group (Group C) 8.84 ± 1.13 6.84 ± 1.12c 3.42 ± 0.66c∗ 2.02 ± 0.27c∗
b,c vs. a P < 0.05.
∗ vs. b P < 0.05.
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FIGURE 3 | TUNEL findings of the ischemia group at 28 days after
sham transplantation.
FIGURE 4 | TUNEL findings of MSCs group at 28 days after
transplantation.
FIGURE 5 | TUNEL findings of GDNF+MSCs group at 28 days after
transplantation.
IMMUNOHISTOCHEMICAL FINDINGS FOR Bcl-2
Three days after transplantation, the number of Bcl-2 positive
cells in the MSCs group and the MSCs+GDNF group was
greater than that in the ischemia group (P < 0.01). The pos-
itive cells were characterized by a brown color and irregular
appearances such as round-shaped cells, spindle-shaped cells,
or the presence of long processes. It was observed that the
number of Bcl-2 positive cells between the MSCs group and
the MSCs+GDNF group was not different from each other.
However, 14 days after the transplantation, the MSCs+GDNF
group had significantly more Bcl-2 positive cells than the MSCs
group (20.54 ± 2.27, 39.28 ± 3.28, and 45.33 ± 4.06, P < 0.05)
(Figures 6 and 7).
FIGURE 6 | Immunohistochemical findings of MSCs group at 14 days
after transplantation.
FIGURE 7 | Immunohistochemical findings of GDNF + MSCs group at
14 days after transplantation.
DISCUSSION
Under the current situation of the application of gene therapy
for central nervous diseases, it is necessary to find a method by
which the stromal cells can be amplified in large volume through
in vivo within a short time period. As a confirmed cell source with
differentiation potential to nervous tissue, MSCs are expected to
be used for the treatment of diverse nervous diseases because
they are not only present with conspicuous advantages such as
autologous origin and easy harvesting, but they are also absent
from the ethical and immunological rejection problems that
fetal stem cell transplantation often develops (Dawn and Bolli,
2005; Wang et al., 2005). Recent studies showed that (GDNF)
had a nutritive effect not only on dopaminergic neurons but
also on many other central and peripheral motor, sensory, and
sympathetic neurons, functioning to promote the growth, differ-
entiation, and repair of neurons. It also plays an important role
in protecting neurons from injury and in the repair, regenera-
tion and axon formation of an injured neuron (Oppenheim et al.,
1995; Sauer et al., 1996; Wang et al., 2011). As its irreplaceable
role in the nourishment of nervous system, GDNF currently is
a hot spot in the research of neurology.
It was reported that if the ischemic rats were intracerebroven-
tricularly or intraparenchymally administered with exogenous
GDNF protein or adenovirus-mediated GDNF gene, their motor,
sensory, and recognition function would improve greatly, their
cerebral edema scope, apoptotic cell number, and infarction vol-
ume would decrease and the regenerated striatal neurons would
increase (Kobayashi et al., 2006; Androutsellis-Theotokis et al.,
2008). Further studies showed that GDNF could antagonize
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injury induced by reactive oxygen and free radicals through up-
regulating the expression of glutathione peroxidase, hydrogen
peroxidase, and superoxide dismutase (SOD). GDNF could also
reduce the calcium reflux induced by NMDA, a glutamic recep-
tor, via the mitogen activated protein kinase (MAPK) pathway.
Therefore, it was reported that GDNF had a protective effect
on the ischemic brain injury by suppressing the production of
free radicals and active toxics (Nicole et al., 2001; Horita et al.,
2006). The above-mentioned studies showed that GDNF could
inhibit the development of ischemic brain injury via multiple
mechanisms, serving as a potent neuroprotective agent for cere-
bral ischemia. The key of this present study was the construction
of stem cells that were able to secrete GDNF from MSCs pre-
viously transfected with pcDNA3-GDNF-GFP expression vector.
The GDNF modified MSCs transplantation was not only free
from the problems caused by simple GDNF administration such
as low local concentration, short half-life, infection potential
caused by repeated administration and insufficient expression of
plasmids that carry GDNF gene, but also absent of the defects
present in the common stem cell transplantation including the
apoptosis or early death of the transplanted cells due to a shortage
of nutrition.
In the present study, it was revealed that three days after the
animal model was established, a vast number of TUNEL positive
apoptotic cells appeared at the cortex surrounding the infarcted
region. Transplanted MSCs could reduce the production of apop-
totic cells which would be beneficial to the cerebral tissue repair
and nervous function improvement posterior to ischemia. Its
mechanism is probably related to the partial replacement of the
apoptotic cells by the transplanted MSCs and to the secretion of
GDNF which could alleviate cellular apoptosis. The study further
showed that at 14 and 28 days after transplantation, the apoptotic
cells present around the ischemic region in the MSCs+GDNF
transplantation group were significantly fewer than those in the
MSCs group. The Bcl-2 gene is an apoptosis suppressor. Its
expression product is mainly located in the mitochondrial, retic-
ular, and nuclear membranes. The major mechanism of the Bcl-2
protein in apoptosis inhibition is the suppression of the produc-
tion of free radicals and intracellular calcium overloading, reduc-
tion of the permeability of mitochondrial membrane, blocking
of the release of cytochrome C, and inhibition the activation of
caspase (Zhan et al., 2001; Albrecht et al., 2007). MSCs transplan-
tation could up-regulate Bcl-2 expression. Fourteen days after
transplantation, the MSCs+GDNF group had more Bcl-2 posi-
tive cells than the MSCs group suggesting that the MSCs+GDNF
transplantation was preferable over the MSCs transplantation
in reducing apoptotic cell volume and enhancing Bcl-2 expres-
sion, thus playing a more important role in neural function
recovery after an ischemic brain injury. The possible reason
for this may be that the combined application of MSCs and
GDNF up-regulated the expression of anti-apoptotic proteins
and consequently inhibited the cascade reaction during ischemia
(Lasala et al., 2010).
From the above-mentioned discussion, it can be concluded
that the GDNF modified MSCs transplantation is more useful
than common the MSCs transplantation in nervous function
recovery after an ischemic brain injury. Generally, the MSCs
themselves can secrete nerve growth and nutrition factors, but
the secreted volume is too small to meet the needs of neural
cell repair (Mahmood et al., 2004). After GDNF transfection, the
continuously secreted neurotrophic factors can not only improve
the survival of transplanted MSCs, but also nourish and partially
restore the remaining nerve tissue at the ischemic region. This
may contribute to the more favorable efficacy of MSCs+GDNF
transplantation. In previous study (Gage et al., 1995), local intra-
cerebral injection induces local brain damage, and particularly,
multiple injections may not be clinically acceptable. In the study,
the GDNF modified MSCs delivered to ischemic tissue through
an intravenous route can not only function to replace the inher-
ent injured cerebral cells similar to MSCs, but also can improve
the survival andmigration of the transplantedMCSs, promote the
formation of collateral circulation, improve the local microenvi-
ronment and accelerate the recovery of nervous function through
secreted GDNF. This simple approach for cell therapy, which does
not necessitate invasive stereotaxic operations, could potentially
target pathological sites in a number of brain disorders. The fol-
lowing study will focus on the functionality of transplanted cells,
the effect of transplantation on the immune system, and the
detailed mechanism of the activation of signal pathway during
the recovery of nervous function, in order to provide evidence for
the future application of stem cell transplantation in the cerebral
ischemic stroke.
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